Additionally, Cutaneous T-cell Lymphomas (CTCL) are also treated with HDAC class I and II inhibitors including Vorinostat and Romidepsin. The gene discussed is HDAC9; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.